C4x Discovery Holdings plc has advanced its MALT-1 inhibitor program into the preclinical candidate selection phase. Inhibition of MALT-1 has potential therapeutic applicability as a monotherapy for MALT-1-driven cancers and in combination with BTK inhibitors across multiple hematological indications, as well as broader potential in solid tumors and inflammation.
Tuojie Biotech (Shanghai) Co. Ltd. has identified mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of cancer, inflammation and autoimmune diseases.
